Jefferies Upgrades Tango Therapeutics to Buy, Raises Price Target to $60

Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

0.00

Jefferies analyst Maury Raycroft upgrades Tango Therapeutics (NASDAQ: TNGX) from Hold to Buy and raises the price target from $27 to $60.